Zydus Therapeutics' saroglitazar drug granted priority review by US FDA – The Economic Times

Zydus Therapeutics’ saroglitazar drug granted priority review by US FDA  The Economic TimesFDA Grants Priority Review to Saroglitazar NDA for Primary Biliary Cholangitis  HCPLiveZydus eyes Q4 FY27 US launch for liver disease drug after FDA review  Business StandardZydus Saroglitazar NDA gets US FDA Priority Review for PBC  scanx.tradeZydus Therapeutics New Drug Application (NDA) for Saroglitazar to Treat Primary Biliary Cholangitis (PBC) Granted Priority Review by the US FDA  PR Newswire